Jabez Biosciences is a clinical-stage biotechnology company that is developing small molecule inhibitors for the treatment of both solid and liquid cancers. Our lead drug candidate, JBZ-001, is a small molecule inhibitor of a crucial enzyme involved in the de novo synthesis of pyrimidine nucleotides, DHODH, that displays highly optimized therapeutic qualities.
CancerResearch, Oncology, CancerTreatment, Biotech, JabezBioscience, BiotechInvesting, StockInvesting, Investing, Stocks
